Connect with us

News

PharmaCyte Biotech Successfully Completes 9-Month Stability Study

gbafNews28

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps„¢ final product, which will be used in the companys planned clinical trial in locally advanced, inoperable pancreatic cancer.

PharmaCytes Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, The product stability studies of our CypCaps„¢ product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we are answering the questions raised by the FDA following our IND submission. We are also starting additional studies designed to provide information that the FDA has requested, which are mainly focused on the handling of the CypCaps„¢ product in the clinic, and on additional animal data to add to the data that we have already supplied in our IND package.

The ongoing stability study is designed to determine the shelf life of the Cell-in-a-Box encapsulated cell product, CypCaps„¢, frozen at -80°C, and I am pleased to report that the nine-month time point was recently reached and that CypCaps„¢ passed all of the necessary tests, including cell viability, enzyme activity and cell potency, pH, label check, capsule appearance and integrity. This nine-month data, as well as all future longer-term time points of the shelf life analyses, such as the next milestone, the 12-month time point, will be reported to the FDA as an update to our submitted IND.

To learn more about PharmaCytes pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the companys documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCytes therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or cancer-killing form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patients tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a bio-artificial liver and activate the chemotherapy drug at the site of the cancer. This targeted chemotherapy has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCytes therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a bio-artificial pancreas for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCytes Investor Relations Department.

Dr. Gerald W. Crabtree

Investor Relations:

PharmaCyte Biotech, Inc.

Investor Relations Department

Telephone: 917.595.2856

Email: [email protected]

News

MEDIA ALERT – Wolters Kluwer examines taxpayer considerations ahead of the upcoming tax season start date

gbafNews28

Wolters Kluwer Tax & Accounting:

What: The Internal Revenue Service (IRS) announced that it will start accepting and processing 2020 tax returns on February 12, 2021. It stated that the start date was selected to ensure the security and readiness of key tax processing systems and to address the potential impact of recent tax legislation on 2020 tax returns. The Consolidated Appropriations Act, 2021, enacted on December 27, 2020, included many tax provisions with a potential impact on 2020 tax returns.

  • In 2020, the January 27 start date was impacted by the passage of the Consolidated Appropriations Act, 2020, enacted late in 2019
  • In 2019, the January 28 start date was impacted by the government shutdown
  • In 2018, the January 29 start date was impacted by the passage of the Tax Cuts and Jobs Act, enacted late in 2017

Why: The start date is important for taxpayers looking to receive tax refunds as soon as possible and for tax return preparers looking to balance workload during the tax filing season. Factors to consider with the announced start date include the following.

  • Year-end tax changes with a potential impact on 2020 tax returns include: additional economic stimulus payments; allowing the employee retention credit even if you have a Paycheck Protection Program (PPP) loan forgiven; deducting PPP expenses; allowing 2019 Adjusted Gross Income for the Earned Income Tax Credit or Additional Child Tax Credit; disaster relief; 30-year depreciation of residential rental property; and Covid-related expenses qualifying for the educator expense deduction
  • Many of the tax changes enacted in 2020 could also impact 2018 and 2019 tax returns, so 2018 and 2019 amended tax returns should also be considered
  • Some forms that taxpayers should start assembling for tax return preparation include: Form W-2; various Form 1099s, including the new Form 1099-NEC for non-employee compensation and Form 1099-G for certain government payments, such as unemployment benefits; and Notices 1444 and 1444-B for the recovery rebate credit
  • Besides the new recovery rebate on Line 30 of Form 1040, also new on the form is a move of a virtual currency question to the top of Form 1040; the new charitable deduction for non-itemizers on Line 10b; and the reporting of estimated tax payments on Line 26
  • The IRS is still prohibited by law from issuing tax refunds for tax returns claiming certain tax breaks until February 15, 2021 and estimates refunds for those returns will not be issued until early March
  • The IRS continues to encourage electronic filing of tax returns and choosing direct deposit for faster refunds & more accurate returns
  • The due date for individual tax returns is April 15, 2021, with no additional days due to weekends or holidays this year, although some tax preparers are requesting that, due to the later start date, the due date be correspondingly extended

Wolters Kluwer Tax Briefing: Wolters Kluwer Tax & Accounting published the 2020 Tax Year-In‘Review expert briefing that highlights tax code changes made in 2020 and a look ahead for 2021 and beyond.

Who: Federal tax expert Mark Luscombe, JD, LL.M, CPA, Principal Federal Tax Analyst at Wolters Kluwer Tax & Accounting, is available to discuss issues around the start of tax filing season.

PLEASE NOTE: The content of this article is designed to provide accurate and authoritative information in regard to the subject matter covered. The information is provided with the understanding that Wolters Kluwer Tax & Accounting is not engaged in rendering legal, accounting, or other professional services.

Contact: To arrange interviews with Mark Luscombe and other federal and state tax experts from Wolters Kluwer Tax & Accounting on this or any other tax-related topic, please contact Bart Lipinski.

BART LIPINSKI

847-267-2225

[email protected]

Continue Reading

News

Equity Trust Company Launches myEQUITY Connect API to Streamline IRA Investing

gbafNews28

Equity Trust Company (Equity Trust), a leading, technology-enabled financial services company offering alternative asset custody in retirement accounts, announced the launch of myEQUITY Connect, an application programming interface (API) that allows investment platforms, metals dealers, and advisors to integrate with Equity Trust Company to create seamless investor interactions.

The launch of myEQUITY Connect underscores Equity Trusts commitment to the development of best-in-class technology solutions. myEQUITY Connect provides endpoints that deliver connection throughout the entire lifecycle from opening and funding an IRA, to submitting an investment request, as well as real-time access to the data to track and monitor activities and cash availability.

myEQUITY Connect allows for a streamlined and simplified investor experience, said Jessica Hunley, Senior Product Manager, Digital Experience. Allowing for platforms to keep the investor on their site and leverage technology to link systems together and automate the processing of the requests.

Equity Trust anticipates the needs of todays investment platforms, metals dealers, and advisors, helping build important relationships that drive growth in an ever-changing landscape. The API suite will streamline and simplify the investing process for investors by allowing them to stay in one place to direct their IRA funds. Platforms, metals dealers, and advisors have the advantage of developing an experience that allows them to tap into the $11.3 trillion* IRA market. myEQUITY Connect promotes flexibility for partners to select full, end-to-end, or targeted integrations that support reduction in attrition and delays in the handover to IRA custodians with this toolkit.

A new developer portal enables developers to easily access all the APIs available. Through this portal, Equity Trust will provide developers with technical documentation and reference guides to support the API integrations. To get started or for more information about myEQUITY Connect, please visit: https://myequityconnect.com.

*As of September 2020. Investment Company Institute, ici.org

ABOUT EQUITY TRUST COMPANY

Equity Trust Company is a financial services company that enables individual investors and financial professionals to diversify investment portfolios using alternative asset classes such as real estate, tax liens, private equity, cryptocurrency, and precious metals. The Equity Trust family of companies offers custodial services for alternative investments and back-office solutions for Registered Investment Advisors, brokerage services, directed trustee services and more. Equity Trust Company is the trusted custodian and administrator of $28.7 billion in assets on behalf of more than 170,000 clients as of March 1, 2020.

For more information, visit https://www.trustetc.com/. Financial professionals visit https://www.equityinstitutional.com.

Equity Trust Company is a directed custodian and does not provide tax, legal or investment advice. Any information communicated by Equity Trust Company is for educational purposes only, and should not be construed as tax, legal or investment advice. Whenever making an investment decision, please consult with your tax attorney or financial professional.

Jessica Hunley

(P) 888 382 4727 x7256

[email protected]

Continue Reading

News

Gartner to Present at the Goldman Sachs Technology and Internet Conference

gbafNews28

Gartner, Inc. (NYSE: IT), the worlds leading research and advisory company, today announced that Craig Safian, Executive Vice President and Chief Financial Officer, will present at the Goldman Sachs Technology and Internet Conference.

Gartners presentation is scheduled for 2:50 pm ET on Thursday, February 11, 2021. A link to the live webcast of the presentation will be available via the Company’s web site at http://investor.gartner.com. A replay of the webcast will be available for approximately 30 days following the presentation.

About Gartner

Gartner, Inc. (NYSE: IT), is the world’s leading research and advisory company and a member of the S&P 500. We equip business leaders with indispensable insights, advice and tools to achieve their mission-critical priorities and build the successful organizations of tomorrow.

Our unmatched combination of expert-led, practitioner-sourced and data-driven research steers clients toward the right decisions on the issues that matter most. We are a trusted advisor and an objective resource for more than 14,000 enterprises in more than 100 countries across all major functions, in every industry and enterprise size.

To learn more about how we help decision makers fuel the future of business, visit www.gartner.com.

Gartner-IR

David Cohen

GVP, Investor Relations, Gartner

+1 203.316.6631

Kathleen Persaud

Director, Investor Relations, Gartner

+1 203.316.1672

[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News44 mins ago

Bonitasoft Sets New Standard for Open Source Digital Process Automation, Delivering Innovation for Project Collaboration and Governance

Bonitasoft, open source digital process automation company, today announced a significant milestone in the democratization of process automation technologies. To...

gbafNews28 gbafNews28
News44 mins ago

Gartner to Present at the Goldman Sachs Technology and Internet Conference

Gartner, Inc. (NYSE: IT), the worlds leading research and advisory company, today announced that Craig Safian, Executive Vice President and...

gbafNews28 gbafNews28
News44 mins ago

Equity Trust Company Launches myEQUITY Connect API to Streamline IRA Investing

Equity Trust Company (Equity Trust), a leading, technology-enabled financial services company offering alternative asset custody in retirement accounts, announced the...

gbafNews28 gbafNews28
News44 mins ago

MEDIA ALERT – Wolters Kluwer examines taxpayer considerations ahead of the upcoming tax season start date

Wolters Kluwer Tax & Accounting: What: The Internal Revenue Service (IRS) announced that it will start accepting and processing 2020...

gbafNews28 gbafNews28
News55 mins ago

Traxo and Smart Hotel Rate Partner to Automatically Apply Corporate Negotiated Rates and Discounts to Direct Hotel Bookings

Traxo, Inc., the global leader in real-time corporate travel data capture and intelligence, today announced a partnership with New York-based...

gbafNews28 gbafNews28
News59 mins ago

Blackline Safety Closes Record Year with 42% Increase in Recurring Revenue and $38.4M Overall Revenue

Blackline Safety Corp. (TSX.V: BLN), a global leader in connected safety technology with a recurring revenue business model, announced $11.6M...

gbafNews28 gbafNews28
News1 hour ago

CSI’s 2021 Banking Priorities Executive Report: Cybersecurity Threats and Digital Transformation Top of Mind on the Heels of a Pandemic

Computer Services, Inc. (CSI) (OTCQX: CSVI), a provider of end-to-end fintech and regtech solutions, has released the findings from its...

gbafNews28 gbafNews28
News1 hour ago

Insights on the IIoT Data Collection and Device Management Platform Market 2021-2025: COVID-19 Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024 – Technavio

The IIoT data collection and device management platform market is expected to grow by $ 1.38 bn, decelerate at a...

gbafNews28 gbafNews28
News1 hour ago

Western Union to Release Fourth Quarter and Full Year Results on February 10, 2021

The Western Union Company (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, announced today that Chief...

gbafNews28 gbafNews28
News1 hour ago

Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that...